Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more
Start a new interaction query Switch to Table View

Generate a personalised report in PDF format

Do Not Coadminister

Darunavir/cobicistat (DRV/c)

Simvastatin

Quality of Evidence: Very Low

Summary:

Coadministration is contraindicated as it is expected to markedly increase simvastatin concentrations which may cause myopathy, including rhabdomyolysis.

Description:

Based on theoretical considerations darunavir/cobicistat is expected to increase simvastatin plasma concentrations (CYP3A inhibition and/or transport). Concomitant use of darunavir/cobicistat with simvastatin is contraindicated due to the potential for serious and/or life-threatening adverse reactions.
Rezolsta Summary of Product Characteristics, Janssen-Cilag Ltd, July 2023.

Coadministration is expected to increase concentrations of simvastatin. Coadministration is contraindicated due to the potential for serious reactions, such as myopathy including rhabdomyolysis.
Prezcobix US Prescribing Information, Janssen Pharmaceuticals Inc, March 2023.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2024 The University of Liverpool. All rights reserved.